Form 8-K Intra-Cellular Therapies For: Oct 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Intra-Cellular Therapies (ITCI) PT Raised to $79 at Goldman Sachs
October 30, 2024 4:38 PM EDTGoldman Sachs analyst Corinne Jenkins raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $79.00 (from $74.00) while maintaining a Neutral rating.
The analyst comments "Focus remains on commercial execution ahead of MDD launch. ITCI reported 3Q24 revenues of $175.4M, slightly higher than FactSet consensus ($172.3M, +2%) and in-line with GS estimate ($175.2M, 0%). The company also modestly raised and narrowed the range... More
